If you are reading this, chances are that you already know the great  potential that NGAL holds. Not only as a revolutionizing Biomarker.

But you might ask yourself , “is it possible to invest in a public listed company, where NGAL is the MAIN business, and where the potential in NGAL is yet to be […]

Abbott submission for EPO OD Oral Proceedings

News from EPOLINE:

Abbott submits roughly 200 pages for “clarification” in regards to the oral proceedings.

(The link only contains a few, “clarifying” pages though)

As mentioned in the MedicoInvestor Presentation NGAL for Dummies, Inflammation and cancer will often result in higher NGAL values, than what is present in normal healthy individuals. NGAL is not exclusively produced by the Kidneys, but also from whote blood cells, and other types of tissue.

This Chinese survey demonstrates that higher values than normal […]

NGAL Clinical Communication Platform

Besides the cut-offs, which certainly appears in line with BioPorto’s patent, it is firmly established that;

– AKI is a common problem with increasing incidents. It is associated with high levels of serious complications, costs and mortality.
– The current Diagnosis of AKI is primarily based on serum creatinine, which […]